Pericoronary Adipose Tissue: A Novel Therapeutic Target in Obesity-Related Coronary Atherosclerosis

Journal of the American College of Nutrition

Volumn 34, Issue 3, 2015, Pages 244-254

  Mazurek, Tomasz ^a   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

insulin resistance, metabolism, obesity, type 2 diabetes, body composition

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; FAT; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; BODY MASS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; HUMAN; OBESITY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; WEIGHT GAIN; COMPLICATION; CORONARY BLOOD VESSEL; INFLAMMATION; PATHOLOGY; PERICARDIUM; PHYSIOLOGY;

ADIPOKINES; ADIPOSE TISSUE; CORONARY ARTERY DISEASE; CORONARY VESSELS; HUMANS; INFLAMMATION; OBESITY; PERICARDIUM; SIGNAL TRANSDUCTION;

EID: 84929606689     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2014.933685     Document Type: Article

References (103)

1. P.K.Siiteri: Adipose tissue as a source of hormones. Am J Clin Nutr 45:277–282, 1987.
2. J.S.Flier, K.S.Cook, P.Usher, B.M.Spiegelman: Severely impaired adipsin expression in genetic and acquired obesity. Science 237:405–408, 1987.
3. Y.Zhang, R.Proenca, M.Maffei, M.Barone, L.Leopold, J.M.Friedman: Positional cloning of the mouse obese gene and its human nomologue. Nature 372:425–432, 1994.
4. G.Fruhbeck, J.Gomez-Ambrosi, F.J.Muruzabal, M.A.Burrell: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280:E827–E847, 2001.
5. J.N.Fain, A.K.Madan, M.L.Hiler, P.Cheema, S.W.Bahouth: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:2273–2282, 2004.
6. S.K.Fried, D.A.Bunkin, A.S.Greenberg: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850, 1998.
7. K.Kohchi, S.Takebayashi, T.Hiroki, M.Nobuyoshi: Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results of autopsy. Circulation 71:709–716, 1985.
8. M.B.Forman, J.A.Oates, D.Robertson, R.M.Robertson, L.J.Roberts, R.Virmani: Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 313:1138–1141, 1985.
9. P.Moreno, R.Purushothaman, V.Fuster, W.N.O'Connor: Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta. Implications for plaque vulnerability. Circulation 105:2504–2511, 2002.
10. P.Laine, A.Naukkarinen, L.Heikkila, A.Penttilä, P.T.Kovanen: Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. Circulation 101:1665–1669, 2000.
11. F.D.Kolodgie, R.Virmani, J.F.Cornhill, E.E.Herderick, J.Smialek: Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol 17:1553–1560, 1991.
12. M.F.Prescott, C.K.McBride, M.Court: Development of intimal lesions after leukocyte migration into the vessel wall. Am J Pathol 135:835–846, 1989.
13. K.Miyata, H.Shimokawa, T.Kandabashi, T.Higo, K.Morishige, Y.Eto, K.Egashira, K.Kaibuchi, A.Takeshita: Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vasc Biol 20:2351–2358, 2000.
14. H.Shimokawa, A.Ito, Y.Fukumoto, T.Kadokami, R.Nakaike, M.Sakata, T.Takayanagi, K.Egashira, A.Takeshita: Chronic treatment with interleukin-1⇓ induces coronary intimal lesions and vasospastic responses in pigs in vivo. J Clin Invest 97:769–776, 1996.
15. A.C.Berger, R.Beeuwkes, L.L.Lainey, K.J.Silverman: Hypothesis: vasa vasorum and neovascularisation of human coronary arteries. A possible role in the pathology of atherosclerosis. N Engl J Med 310:175–177, 1984.
16. Y.Zhang, W.J.Cliff, G.I.Schoefl, G.Higgins: Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol 143:164–172, 1993.
17. E.Brogi, J.A.Winkles, R.Underwood, S.K.Clinton, G.F.Alberts, P.Libby: Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. J Clin Invest 92:2408–2418, 1993.
18. M.A.Lovich, E.R.Edelman: Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Natl Acad Sci USA 96:11111–11116, 1999.
19. R.Ross: Mechanisms of disease: atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126, 1999.
20. H.C.Stary, A.B.Chandler, S.Glagov, J.R.Guyton, W.InsullJr, M.E.Rosenfeld, S.A.Schaffer, C.J.Schwartz, W.D.Wagner, R.W.Wissler: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89:2462–2468, 1994.
21. C.Napoli, F.P.D'Armiento, F.P.Mancini, A.Postiglione, J.L.Witztum, G.Palumbo, W.Palinski: Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 100:2680–2690, 1997.
22. R.Virmani, A.P.Burke, A.Farb, F.D.Kolodgie: Pathology of vulnerable plaque. JACC 47(8):C13–C18, 2006.
23. S.Tommasi, E.Carluccio, M.Bentivoglio, M.Buccolieri, M.Mariotti, M.Politano, L.Corea: C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 83:1595–1599, 1999.
24. I.Jialal, D.Stein, D.Balis, S.M.Grundy, B.Adams-Huet, S.Devaraj: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1942–1958, 2001.
25. G.Liuzzo, L.M.Biasucci, J.R.Gallimore, R.L.Grillo, A.G.Rebuzzi, M.B.Pepys, A.Maseri: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–423, 1994.
26. L.Zhang, A.Zalewski, Y.Liu, T.Mazurek, S.Cowan, J.L.Martin, S.M.Hofmann, H.Vlassara, Y.Shi: Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108:472–478, 2003.
27. T.Pischon, H.Boeing, K.Hoffmann, Bergmann M, Schulze B, Overvad K, van der Schouw YT, Spencer E, Moons KGM, Tjønneland A Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault M-C, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, M Peeters, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJB, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E: General and abdominal adiposity and risk of death in Europe. N Engl J Med 359:2105–2120, 2008.
28. S.Klein, L.E.Burke, G.A.Bray, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110:2952–2967, 2004.
29. S.E.Litwin: Which measures of obesity best predict cardiovascular risk? J Am Coll Cardiol 52:616–619, 2008.
30. C.Lavie, R.V.Milani, H.O.Ventura: Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53:1925–1932, 2009.
31. D.Smith, S.D.Irving, J.Sheldon, D.Cole, J.C.Kaski: Serum levels of the inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104:746, 2001.
32. Patel S, Shi Y, Niculescu R, Chung EH, Martin JL, Zalewski A. Characteristics of coronary smooth muscle cells and adventitial fibroblasts. Circulation 101:524–32.
33. S.K.Fried, D.A.Bunkin, A.S.Greenberg: Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850, 1998.
34. P.Arner: Regional differences in protein production by human adipose tissue. Biochem Soc Trans 29:72–75, 2001.
35. M.Kaartinen, A.Penttila, P.T.Kovanen: Mast cells accompany microvessels in human coronary atheromas: implications for intimal neovascularisation and hemorrhage. Atherosclerosis 123:123–131, 1996.
36. T.Mazurek, L.Zhang, A.Zalewski, J.D.Mannion, J.T.Diehl, H.Arafat, L.Sarov-Blat, S.O'Brien, E.A.Keiper, A.G.Johnson, J.Martin, B.J.Goldstein, Y.Shi: Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108:2460–2466, 2003.
37. A.De Vos, M.Prokop, C.Roos, M.Meijs, Y.Van der Schouw, A.Rutten, P.Gorter, M.-J.Cramer, P.Doevendans, B.Rensing, M.-L.Bartelink, B.Velthuis, A.Mosterd, M.Bots: Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J 29:777–783, 2008.
38. H.S.Sacks, J.N.Fain: Epicardial adipose tissue—a review. Am Heart J 153:907–917, 2007.
39. J.S.Yudkin, E.Eringa, C.D.A.Stehouwer: “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365:1817–1820, 2005.
40. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG: Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 5:1, 2006.
41. Greif M, Becker A, von Ziegler F, Lebherz C, Lehrke M, Broedl UC, Tittus J, Parhofer K, Becker C, Reiser M, Knez A, Leber AW: Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 29:781–786, 2009.
42. T.Mazurek: Proinflammatory capacity of adipose tissue—a new insights in the pathophysiology of atherosclerosis. Kardiol Pol 67:1119–1124, 2009.
43. S.N.Verhagen, F.L.Visseren: Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 214:3–10, 2011.
44. Gorter PM, van Lindert AS, de Vos AM, Meijs MF, van der Graaf Y, Doevendans PA, Prokop M, Visseren FL: Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis 197:896–903, 2008.
45. C.S.Fox, P.Gona, U.Hoffmann, S.A.Porter, C.J.Salton, J.M.Massaro, D.Levy, M.G.Larson, R.B.D'Agostino, C.J.O'Donnell, W.J.Manning: Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function. The Framingham Heart Study. Circulation 119:1586–1591, 2009.
46. T.Mazurek, R.Nijveldt, J.S.Yudkin, A.Hirsch, Y.Smulders, A.C.Van Rossum: Peri-coronary epicardial adipose tissue affects coronary atherosclerosis in patients with acute myocardial infarction. Circulation 118:S580–S581, 2008.
47. Montalescot G, Van de Werf F, Gulba DC, Avezum A, Brieger D, Kennelly BM, Mazurek T, Spencer F, White K, Gore JM: Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE). Catheter Cardiovasc Interv 60:360–367, 2003.
48. A.Mahabadi, N.Reinsch, N.Lehmann, J.Altenbernd, H.Kälsch, R.M.Seibel, R.Erbel, S.Möhlenkamp: Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 211:195–199, 2010.
49. A.Mahabadi, M.H.Berg, N.Lehmann, H.Kälsch, M.Bauer, K.Kara, N.Dragano, S.Moebus, K.-H.Jockel, R.Erbel, S.Möhlenkamp: Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population. J Am Coll Cardiol 61:1388–1395, 2013.
50. G.Iacobellis, H.J.Willens: Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 22:1311–1319, 2009.
51. K.Aziz, K.Berger, K.Claycombe, R.Huang, R.Patel, G.S.Abela: Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 117:2061–2070, 2008.
52. J.Bucerius, V.Mani, C.Moncrieff, J.Machac, V.Fuster, M.E.Farkouh, A.Tawakol, J.H.F.Rudd, Z.A.Fayad: Optimizing (18)F-FDG PET/CT imaging of vessel wall inflammation: the impact of (18)F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med 41:369–383, 2013.
53. M.Ogawa, Y.Magata, T.Kato, K.Hatano, S.Ishino, T.Mukai, M.Shiomi, K.Ito, H.Sai: Application of 18-F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med 47:1845–1850, 2007.
54. N.Tahara, H.Kai, H.Nakaura, M.Mizoguchi, M.Ishibashi, H.Kaida, K.Baba, N.Hayabuchi, T.Imaizumi: The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose–positron emission tomography. E Heart J 28:2243–2248, 2007.
55. Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ: Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 12:294–301, 2005.
56. T.Mazurek, J.Kochman, M.Kobylecka, R.Wilimski, K.Filipiak, L.Królicki, G.Opolski: Inflammatory activity of pericoronary adipose tissue may affect plaque composition in patients with acute coronary syndrome without persistent ST-segment elevation: preliminary results. Kardiol Pol 72:410–416,2013.
57. T.Mazurek, M.Kiliszek, M.Kobylecka, J.Kochman, K.Filipiak, L.Królicki, J.Skubisz-Głuchowska, G.Opolski: Proinflammatory activity of epicardial adipose tissue may affect the occurrence of atrial fibrillation. Am J Cardiol 113:1505–1508, 2013.
58. A.Tawakol, P.Singh, J.H.F.Rudd, J.Soffer, G.Cai, E.Vucic, S.P.Brannan, E.A.Tarka, B.C.Shaddinger, L.Sarov-Blat, P.Matthews, S.Subramanian, M.Farkouh, Z.A.Fayad: Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-PET Imaging. J Am Coll Cardiol 63:86–88, 2014.
59. K.M.Mäki-Petäjä, M.Elkhawad, J.Cheriyan, F.R.Joshi, A.J.K.Östör, F.C.Hall, J.H.F.Rudd, I.B.Wilkinson: Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 126:2473–2480, 2012.
60. A.Tawakol, Z.A.Fayad, R.Mogg, A.Alon, M.T.Klimas, H.Dansky, S.S.Subramanian, A.Abdelbaky, J.H.F.Rudd, S.S.Shankar: Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 62:909–917, 2013.
61. M.Elkhawad, J.H.Rudd, L.Sarov-Blat, G.Cai, R.Wells, L.C.Davies, D.J.Collier, M.S.Marber, R.P.Choudhury, Z.A.Fayad, A.Tawakol, F.V.Gleeson, J.J.Lepore, B.Davis, R.N.Willette, I.B.Wilkinson, D.L.Sprecher, J.Cheriyan: Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging 5:911–922, 2012.
62. N.V.Joshi, A.T.Vesey, M.C.Williams, A.S.Shah, P.A.Calvert, F.H.Craighead, S.E.Yeoh, W.Wallace, D.Salter, A.M.Fletcher, E.J.van Beek, A.D.Flapan, N.G.Uren, M.W.Behan, N.L.Cruden, N.L.Mills, K.A.Fox, J.H.Rudd, M.R.Dweck, D.E.Newby: 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2013.
63. Kumada M, Kihara S, Ouchi N, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046–2049, 2004.
64. Fesus G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, Gollasch M: Adiponectin is a novel humoral vasodilator. Cardiovasc Res 75:719–727, 2007.
65. Malinowski M, Deja MA, Golba KS, Roleder T, Biernat J, Woś S: Perivascular tissue of internal thoracic artery releases potent nitric oxide and prostacyclin-independent anticontractile factor. Eur J Cardiothorac Surg 33:225–231, 2008.
66. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737, 2004.
67. A.S.Greenstein, K.Khavandi, S.B.Withers, K.Sonoyama, O.Clancy, M.Jeziorska, I.Laing, A.P.Yates, P.W.Pemberton, R.A.Malik, A.M.Heagerty: Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119:1661–1670, 2009.
68. G.Deng, Y.Long, Y.R.Yu, M.R.Li: Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) 34:165–171, 2010.
69. K.Karastergiou, I.Evans, N.Ogston, N.Miheisi, D.Nair, J.C.Kaski, M.Jahangiri, V.Mohamed-Ali: Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol 30: 1340–1346, 2010.
70. C.Y.Chen, M.Asakura, H.Asanuma, T.Hasegawa, J.Tanaka, N.Toh, K.-D.Min, H.Kanzaki, H.Tahanama, M.Amaki, Y.Itoh, G.Ichien, Y.Okumoto, T.Funahashi, J.Kim, M.Kitakaze: Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels. Hypertens Res 35:843–848, 2012.
71. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 409:307–312, 2001.
72. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation 108:736–740, 2003.
73. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci G, Maffei A, Cifelli G, Iorio L, Landolfi A, Frati G, Lembo G: Resistin impairs insulin-evoked vasodilation. Diabetes 57:577–583, 2008.
74. Weikert C, Westphal S, Berger K, Dierkes J, Möhlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 93:2647–2653, 2008.
75. J.Beltowski: Leptin and atherosclerosis. Atherosclerosis 189:47–60, 2006.
76. M.L.Correia, W.G.Haynes: Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 13:215–223, 2004.
77. R.Muniyappa, M.Montagnani, K.K.Koh, M.J.Quon: Cardiovascular actions of insulin. Endocr Rev 28:463–491, 2007.
78. J.A.Kim, M.Montagnani, K.K.Koh, M.J.Quon: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113:1888–1904, 2006.
79. A.M.Wallace, A.D.McMahon, C.J.Packard, A.Kelly, J.Shepherd, A.Gaw, N.Sattar: Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104:3052–3056, 2001.
80. P.Piatti, C.Di Mario, L.D.Monti, G.Fragasso, F.Sgura, A.Caumo, E.Setola, P.Lucotti, E.Galluccio, C.Ronchi, A.Origgi, I.Zavaroni, A.Margonato, A.Colombo: Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108:2074–2081, 2003.
81. S.Soderberg, B.Ahren, B.Stegmayr, O.Johnson, P.G.Wiklund, L.Weinehall, G.Hallmans, T.Olsson: Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 30:328–337, 1999.
82. M.L.Gruen, M.Hao, D.W.Piston, A.H.Hasty: Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Am J Physiol Cell Physiol 293:C1481–C1488, 2007.
83. Payne GA, Borbouse L, Kumar S, Neeb Z, Alloosh M, Sturek M, Tune JD: Epicardial perivascular adipose-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a protein kinase C-beta pathway. Arterioscler Thromb Vasc Biol 30:1711–1717, 2010.
84. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL: Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 104:541–549, 2009.
85. G.Iacobellis, H.J.Willens, G.Barbaro, A.M.Sharma: Threshold values of high-risk echocardiographic epicardial fat thickness. Obesity 16:887–892, 2008.
86. T.Mazurek, M.Kobylecka, R.Wilimski, J.Kochman, K.Filipiak, L.Krolicki, G.Opolski: Inflammatory capacity of pericoronary adipose tissue among overweight patients with stable angina affects atherosclerotic leasions formation. Eur Heart J 34:959, 2013.
87. C.K.Kramer, B.Zinman, R.Retnakaran: Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med 159:758–769, 2013.
88. G.Iacobellis, A.M.Sharma: Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 13:2180–2184, 2007.
89. A.P.Rossi, F.Fantin, G.A.Zamboni, G.Mazzali, E.Zoico, C.Bambace, A.Antonioli, R.Pozzi Mucelli, M.Zamboni: Effect of moderate weight loss on hepatic, pancreatic and visceral lipids in obese subjects. Nutr Diabetes 2(3):e32, 1–7, 2012.
90. C.J.Lavie, R.V.Milani, H.O.Ventura: Obesity and cardiovascular disease. Risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53:1925–1932, 2009.
91. M.Hamer, S.M.Venuraju, L.Urbanova, A.Lahiri, A.Steptoe: Physical activity, sedentary time, and pericardial fat in healthy older adults. Obesity (Silver Spring) 20:2113–2117, 2012.
92. D.Gao, P.Trayhurn, C.Bing: 1,25-Dihydroxy vitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond) 37:357–365, 2013.
93. K.Yamashita, H.Yatsuya, T.Muramatsu, H.Toyoshima, T.Murohara, K.Tamakoshi: Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study. Nutr Diabetes 2:e33, 1–6, 2012.
94. C.Hilton, M.J.Neville, F.Karpe: MicroRNAs in adipose tissue: their role in adipogenesis and obesity. Int J Obes (Lond) 37:325–332, 2013.
95. I.J.Gallagher, C.Scheele, P.Keller, A.R.Nielsen, J.Remenyi, C.P.Fischer, K.Roder, J.Babraj, C.Wahlestedt, G.Hutvagner, B.K.Pedersen, J.A.Timmons: Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2(2):9, 2010.
96. E.M.Small, E.N.Olson: Pervasiveroles of microRNAs in cardiovascular biology. Nature 469:336–342, 2011.
97. P.Keller, V.Gburcik, N.Petrovic, I.J.Gallagher, J.Nedergaard, B.Cannon, J.A.Timmons: Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity. BMC Endocr Disord 11:7, 2011.
98. D.V.Chartoumpekis, A.Zaravinos, P.G.Ziros, R.P.Iskrenova, A.I.Psyrogiannis, V.E.Kyriazopoulou, I.G.Habeos: Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One 7:e34872, 2012.
99. G.W.Wong, S.A.Krawczyk, C.Kitidis-Mitrokostas, T.Revett, R.Gimeno, H.F.Lodish: Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416:161–177, 2008.
100. H.Xie, B.Lim, H.F.Lodish: MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 58:1050–1057, 2009.
101. G.W.Wong, S.A.Krawczyk, C.Kitidis-Mitrokostas, G.Ge, E.Spooner, C.Hug, R.Gimeno, H.F.Lodish: Identification and characterization of CTRP9, a novel secreted glycoprotein from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J 23:241–258, 2009.
102. J.W.Jonker, J.M.Suh, A.R.Atkins, M.Ahmadian, P.Li, J.Whyte, M.He, H.Juguilon, Y.Q.Yin, C.T.Phillips, R.T.Yu, J.M.Olefsky, R.R.Henry, M.Downes, R.M.Evans: A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485:391–394, 2012.
103. N.Kodama, N.Tahara, A.Tahara, A.Honda, Y.Nitta, M.Mizoguchi, H.Kaida, M.Ishibashi, T.Abe, H.Ikeda, J.Narula, Y.Fukumoto, S.Yamagishi, T.Imaizumi: Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocr Metab 98:4438–4445, 2013.